Monopar Therapeutics (MNPR): Net Income
-$13.72M
Year ended 2025-12-31
-$17.84M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$13.72M | n/m | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | -$15.59M | n/m | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | -$8.40M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$10.52M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$9.10M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | -$6.30M | n/m | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | -$4.22M | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | -$3.23M | n/m | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | -$16.55M | n/m | 2019-02-26, From 2017-01-01 |
| 2016-12-31 | -$1.19M | n/a | 2018-03-26, From 2016-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | 2025-12-31 | -$13.72M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $6.52B | -51.3% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $7.05B | n/m |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$569.0K | n/m |
| Eli Lilly & Co (LLY) | 2025-12-31 | $20.64B | +94.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $7.77B | -3.2% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $26.80B | +90.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $20.45M | +159.1% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $18.25B | +6.6% |
Compare MNPR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗